Compositions for treating CMT and related disorders
The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.
1. A method for treating Charcot Marie Tooth (CMT) in a human subject in need thereof, said method comprising the step of administering to said human subject:
(i) from 1 to 300 μg/kg of the human subject per day of baclofen or a salt thereof,
(ii) sorbitol or a salt thereof, and
(iii) from 1 to 100 μg/kg of the human subject per day of naltrexone or a salt thereof;
and a pharmaceutically suitable excipient or carrier.
2. The method according to claim 1 , wherein the sorbitol is D-sorbitol.
3. The method according to claim 1 , comprising administering to the human subject baclofen in an amount from between 10 and 200 μg/kg of the human subject per day.
4. The method according to claim 1 , comprising administering to the human subject naltrexone in an amount from between 1 and 50 μg/kg of the human subject per day.
5. The method according to claim 1 , comprising administering to the human subject baclofen in an amount from between 10 and 200 μg/kg of the human subject per day and naltrexone in an amount from between 1 and 50 μg/kg of the human subject per day.
6. The method according to claim 1 , comprising administering to the human subject baclofen in an amount from between 60 μg and 18 mg per day and naltrexone in an amount from between 60 μg and 6 mg per day.
7. The method according to claim 1 , comprising administering to the human subject baclofen in an amount from between 60 μg and 12 mg per day and naltrexone in an amount from between 60 μg and 3 mg per day.
8. The method according to claim 1 , wherein baclofen, sorbitol and naltrexone are administered orally to said human subject.
9. The method according to claim 1 , wherein baclofen, sorbitol and naltrexone are administered separately to said human subject.
10. The method according to claim 1 , wherein baclofen, sorbitol and naltrexone are formulated in a liquid formulation.
11. The method according to claim 1 , wherein baclofen, naltrexone and sorbitol are administered to said human subject one to several times daily.
12. The method according to claim 11 , wherein baclofen, naltrexone and sorbitol are administered to said human subject two times daily.
13. The method according to claim 1 , wherein CMT is CMT1A.
14. The method according to claim 1 , wherein baclofen, sorbitol and naltrexone are the sole active ingredients.